nPhase secures $30M in Series D funding, led by Viking Global Investors. This capital injection accelerates nPhase's AI-native clinical data platform. The platform unifies a Unified Data Management System (UDMS) and a Statistical Computing Environment (SCE). It revolutionizes clinical trials. Real-time data ingestion, stream-based harmonization, and agentic AI capabilities streamline drug development. The system handles complex regulatory compliance, accelerating submissions from months to weeks. It serves pharmaceutical companies, CROs, and academic research globally. This investment expands intelligent workflows, moving life sciences beyond fragmented data toward continuous, adaptive research. nPhase aims to transform data aggregation into intelligent execution, rapidly advancing life-saving therapeutics.
A major funding round reshapes clinical research. nPhase has secured $30 million in Series D financing. Viking Global Investors led this significant investment. The capital fuels nPhase’s global expansion. It boosts development of its AI-native clinical data platform. This marks nPhase's first institutional equity raise since 2017. The company demonstrated strong self-sufficiency for nearly a decade.
The nPhase.ai platform represents a significant leap forward. It unifies critical components: a Unified Data Management System (UDMS) and a Statistical Computing Environment (SCE). This integration creates a comprehensive architecture. It manages clinical trial data from start to finish. Real-world data also benefits from this unified approach. The platform connects information seamlessly. It spans from study startup through final regulatory submission.
Traditional clinical research faces significant hurdles. Fragmented data sources plague the industry. Manual processes lead to delays. End-of-study data reconciliation consumes months. nPhase directly addresses these inefficiencies. Its platform aggregates data continuously. Information flows from diverse sources. These include investigator sites, central laboratories, and patient apps. Digital health sensors also contribute. All data feeds into a governed environment as it generates.
This continuous ingestion prevents backlogs. It eliminates the need for extensive end-of-study cleanups. Data is immediately standardized and validated. This "stream-based harmonization" replaces retrospective batch transformations. Clinical teams work with validated data in near real time. Safety monitoring committees gain instant insights. They track adverse events efficiently. Signal detection improves dramatically. Protocol deviations are flagged immediately.
The platform is designed for AI readiness. Data becomes "AI-ready" upon arrival. This foundation empowers advanced AI agents. These agents perform high-volume operational tasks. They identify incoming data discrepancies automatically. They prepare draft statistical programming swiftly. Human experts retain final decision-making authority. This ensures accuracy and compliance. The AI supports, humans govern.
nPhase's Statistical Computing Environment (SCE) is a cornerstone. It converts raw clinical study data. It produces regulatory-compliant datasets. Analysis packages are generated rapidly. Processes traditionally taking four months or more compress into weeks. The SCE automatically translates standardized data. It generates CDISC ADaM (Analysis Data Model) and TFLs (Tables, Figures, Listings). This dramatically accelerates submission timelines. The entire pipeline, from patient encounter to electronic Common Technical Document (eCTD) submission, becomes unbroken and audited.
The new capital specifically targets further development. It will enhance the SCE and UDMS. Investment in agentic AI capabilities will expand. The goal is to automate more workflows across clinical research. This moves organizations beyond mere data collection. It shifts focus to continuous data utilization. The platform supports operational and scientific decisions throughout the trial lifecycle.
nPhase also operates REDCap Cloud EDC. This robust system serves a wide range of clients. Small and midsize sponsors use it. Nonprofit and academic research organizations benefit. Medical technology studies rely on its capabilities. Real-world data programs also leverage REDCap Cloud. This broad reach underscores nPhase’s comprehensive market presence.
The company’s broader strategy is clear. It aims to fundamentally transform clinical research. It seeks to move beyond managing data aggregation. The focus shifts to intelligent execution. This accelerates life-saving therapeutics to patients. The platform creates a governed, deterministic data fabric. This fabric makes sophisticated AI applications possible.
The investment from Viking Global Investors signifies confidence. Viking manages over $54 billion in public and private investments. Their deep expertise in life sciences is crucial. Their understanding of enterprise technology is equally vital. This partnership validates nPhase’s vision. It confirms its established foundation in clinical research. It recognizes the company's clear vision for enterprise-scale AI.
nPhase addresses specific federal initiatives. Programs like ARPA-H’s SURPASS, under HHS’s “Operation TrialBlazer,” envision continuous, adaptive clinical trials. Such programs face industry constraints. Fragmented, batch-processed data currently limits their potential. nPhase provides the technological solution. Its unified platform supports these ambitious goals.
The funding will expand nPhase’s enterprise clinical data business globally. Intelligent workflows will play a larger role. Autonomous agents will become more prevalent across the platform. This systematic approach aims for a future where data works continuously. It empowers faster, more efficient drug development. The transformation impacts every stage of the clinical data lifecycle. This investment marks a pivotal moment for modernizing life sciences. It promises to deliver therapies to patients more quickly and safely. The future of clinical research is intelligent, automated, and unified. nPhase leads this charge.
A major funding round reshapes clinical research. nPhase has secured $30 million in Series D financing. Viking Global Investors led this significant investment. The capital fuels nPhase’s global expansion. It boosts development of its AI-native clinical data platform. This marks nPhase's first institutional equity raise since 2017. The company demonstrated strong self-sufficiency for nearly a decade.
The nPhase.ai platform represents a significant leap forward. It unifies critical components: a Unified Data Management System (UDMS) and a Statistical Computing Environment (SCE). This integration creates a comprehensive architecture. It manages clinical trial data from start to finish. Real-world data also benefits from this unified approach. The platform connects information seamlessly. It spans from study startup through final regulatory submission.
Traditional clinical research faces significant hurdles. Fragmented data sources plague the industry. Manual processes lead to delays. End-of-study data reconciliation consumes months. nPhase directly addresses these inefficiencies. Its platform aggregates data continuously. Information flows from diverse sources. These include investigator sites, central laboratories, and patient apps. Digital health sensors also contribute. All data feeds into a governed environment as it generates.
This continuous ingestion prevents backlogs. It eliminates the need for extensive end-of-study cleanups. Data is immediately standardized and validated. This "stream-based harmonization" replaces retrospective batch transformations. Clinical teams work with validated data in near real time. Safety monitoring committees gain instant insights. They track adverse events efficiently. Signal detection improves dramatically. Protocol deviations are flagged immediately.
The platform is designed for AI readiness. Data becomes "AI-ready" upon arrival. This foundation empowers advanced AI agents. These agents perform high-volume operational tasks. They identify incoming data discrepancies automatically. They prepare draft statistical programming swiftly. Human experts retain final decision-making authority. This ensures accuracy and compliance. The AI supports, humans govern.
nPhase's Statistical Computing Environment (SCE) is a cornerstone. It converts raw clinical study data. It produces regulatory-compliant datasets. Analysis packages are generated rapidly. Processes traditionally taking four months or more compress into weeks. The SCE automatically translates standardized data. It generates CDISC ADaM (Analysis Data Model) and TFLs (Tables, Figures, Listings). This dramatically accelerates submission timelines. The entire pipeline, from patient encounter to electronic Common Technical Document (eCTD) submission, becomes unbroken and audited.
The new capital specifically targets further development. It will enhance the SCE and UDMS. Investment in agentic AI capabilities will expand. The goal is to automate more workflows across clinical research. This moves organizations beyond mere data collection. It shifts focus to continuous data utilization. The platform supports operational and scientific decisions throughout the trial lifecycle.
nPhase also operates REDCap Cloud EDC. This robust system serves a wide range of clients. Small and midsize sponsors use it. Nonprofit and academic research organizations benefit. Medical technology studies rely on its capabilities. Real-world data programs also leverage REDCap Cloud. This broad reach underscores nPhase’s comprehensive market presence.
The company’s broader strategy is clear. It aims to fundamentally transform clinical research. It seeks to move beyond managing data aggregation. The focus shifts to intelligent execution. This accelerates life-saving therapeutics to patients. The platform creates a governed, deterministic data fabric. This fabric makes sophisticated AI applications possible.
The investment from Viking Global Investors signifies confidence. Viking manages over $54 billion in public and private investments. Their deep expertise in life sciences is crucial. Their understanding of enterprise technology is equally vital. This partnership validates nPhase’s vision. It confirms its established foundation in clinical research. It recognizes the company's clear vision for enterprise-scale AI.
nPhase addresses specific federal initiatives. Programs like ARPA-H’s SURPASS, under HHS’s “Operation TrialBlazer,” envision continuous, adaptive clinical trials. Such programs face industry constraints. Fragmented, batch-processed data currently limits their potential. nPhase provides the technological solution. Its unified platform supports these ambitious goals.
The funding will expand nPhase’s enterprise clinical data business globally. Intelligent workflows will play a larger role. Autonomous agents will become more prevalent across the platform. This systematic approach aims for a future where data works continuously. It empowers faster, more efficient drug development. The transformation impacts every stage of the clinical data lifecycle. This investment marks a pivotal moment for modernizing life sciences. It promises to deliver therapies to patients more quickly and safely. The future of clinical research is intelligent, automated, and unified. nPhase leads this charge.